Traynor Capital Management’s Novavax NVAX Stock Holding History

Traynor Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,168	Closed	-$55K	–	161
2016 Q4	$55K	Sell	2,168 -728	-25%	-$21.2K	0.04%	125
2016 Q3	$92K	Buy	+2,896	New	+$374K	0.07%	122

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Traynor Capital Management's NVAX Position: Q1 2017 in Review

Traynor Capital Management sold out of Novavax (NVAX) in Q1 2017, closing a stake of 2,168 shares — an estimated $55K sold.

Traynor Capital Management first reported a position in NVAX in Q3 2016 and held it in 2 quarters. The position peaked at $92K in Q3 2016. 129 funds tracked by Wall St. Rank hold NVAX as of Q1 2017.

Traynor Capital Management reported no remaining Novavax position as of Q1 2017 after selling out during the quarter.
Traynor Capital Management sold 2,168 Novavax shares in Q1 2017, an estimated $55K.
Traynor Capital Management first reported a position in Novavax in Q3 2016 and held it in 2 quarters.
Traynor Capital Management's Novavax position peaked at $92K in Q3 2016.
129 funds tracked by Wall St. Rank held Novavax as of Q1 2017.

Based on Traynor Capital Management's 13F filing for Q1 2017, filed 11 May 2017.